| Filed On | Filing |
|---|---|
| 01 Sep 2026 |
8-K/A: Other Events
On August 28, 2026, the Company announced that it will effect a one-for-ten (1-for-10) reverse stock split of its common stock, par value $0.0001 per share (the “Common Stock”) (the “Reverse Stock Split”). The Reverse Stock Split was app... |
| 12 Jun 2026 |
8-K/A: Financial Statements and Exhibits
The accompanying unaudited pro forma condensed combined financial information gives effect to two acquisitions completed by BiomX Inc. in April 2026: (i) the acquisition from Mandragola of 100% of Mandragola’s shareholdings in DR. Frucht... |
| 30 May 2024 |
8-K/A: Financial Statements and Exhibits
AUDITED FINANCIAL STATEMENTS OF ADAPTIVE PHAGE THERAPEUTICS, INC. |
| 21 Mar 2024 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On March 18, 2024, BiomX Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) reporting the appointment of Dr. Jesse Goodman, Jonathan Leff and Gregory Merril (collectively, the “New Directors”) to serve on the Co... |
| 13 Nov 2019 | 8-K/A: Departure/Election of Directors or Officers; Compensation |
| 04 Nov 2019 | 8-K/A: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +3 more |
Loading...
